drug_type
RELEVANT_DRUG
intervention_type
Cellular Therapy
drug_description
Engineered T cells (autologous or allogeneic) expressing a CD22-specific CAR via lentiviral transduction; IV dosing 2×10^6–1×10^7 CAR-T/kg; targets CD22+ B-cell malignancies through CAR-mediated activation and cytotoxicity.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous or allogeneic T cells engineered to express a CD22-specific chimeric antigen receptor bind CD22 on B‑cell malignancies and, via CAR signaling (CD3ζ ± co‑stimulation), activate, proliferate, secrete cytotoxic granules (perforin/granzymes) and cytokines, mediating MHC‑independent lysis of CD22‑positive tumor cells.
drug_name
CD22-directed CAR T cells
nct_id_drug_ref
NCT06849921